The Role of PPM1D Mutations in Lenalidomide Resistance and Progression in Patients with MDS and Deletion of Chromosome 5q

Conclusion: PPM1D mutations are recurrently found in MDS del(5q) patients at a frequency of 5.3% and may be coexpressed with TP53 mutations in 5q- MDS/AML cells. Frequency at resistance/AML progression was 18% for PPM1D and 53% for TP53 mutated patients, respectively. Our findings indicate an association of PPM1D mutations in addition to the previously described TP53 mutations with lenalidomide resistance and AML progression.DisclosuresMeggendorfer: MLL Munich Leukemia Laboratory: Employment. Krönke: Celgene: Honoraria. Haferlach: MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Thiede: Novartis: Honoraria, Research Funding; AgenDix: Other: Ownership. Germing: Janssen: Honoraria; Novartis: Honoraria, Research Funding; Celgene: Honoraria, Research Funding. Kobbe: Amgen: Honoraria, Research Funding; Roche: Honoraria, Research Funding; Celgene: Honoraria, Other: Travel Support, Research Funding. Koenecke: Amgen: Consultancy; Roche: Consultancy; abbvie: Consultancy; BMS: Consultancy. Sperr: Novartis: Honoraria; Pfizer: Honoraria; Daiichi Sankyo: Honoraria. Valent: Novartis: Honoraria; Pfizer: Honoraria; Incyte: Honoraria. Ganser: Novartis: Membership on an entity's Board of Directors or advisory committees. Haferlach: MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Platzbecker: Celgene: Research Funding. Heuser: BergenBio: Research Funding; StemLine Therapeutics: Consultancy; Astellas: Research Funding; Novartis: Consultancy, Honoraria, Research Fu...

Source: Blood - November 21, 2018 Category: Hematology Authors: Panagiota, V., Meggendorfer, M., Kubasch, A. S., Gabdoulline, R., Kronke, J., Shahswar, R., Mies, A., Kandziora, C., Klement, P., Schiller, J., Gohring, G., Haferlach, C., Ganster, C., Shirneshan, K., Gutermuth, A., Thiede, C., Germing, U., Schroeder, T., Tags: 637. Myelodysplastic Syndromes-Clinical Studies: Poster III Source Type: research